Category Archives: Nano Medicine

It is my opinion that over the next 5 to 10 years the delivery of medicine will change dramatically. The pharmacist of the future will become the pharmacist of the past. Many years ago, before the incredible sophistication of the pharmaceutical industry, many pharmacists compounded medications in their own facility.

I foresee a situation where a person will go to the doctor following a full assessment of their own genome. A treatment plan will be formulated based on the persons own genetic abnormalities and predispositions. Rather than taking a number of separate pharmaceutical pills and, for those so inclined, vitamin supplements, the doctor will administer a personalised prescription for the person. This will be taken to their pharmacist and, using nanotechnology, all of these therapies will be delivered within the one small pill, taken once daily.

The technology would be advanced to the point where each separate medication within the nano-pill would be released at the appropriate time into the circulation. We are well aware that computer technology power doubles every 18 months and the advances in nanotechnology appear to be mirroring this.

On a separate, but similar, note, the University of Pittsburgh has released recently in the Journal of Investigative Dermatology, a fingertip patch with 400 microneedles for vaccine delivery for live or attenuated vaccines.

The microneedles are made from three-dimensional sugar structures incorporated into what is known as a multicomponent dissolving microneedle array. Interestingly, this not only induces an antibody response but also improves the cellular response better than standard vaccines given via injection. It appears from the preliminary studies that this will induce a strong and long-lasting immunity. The researchers trialled this in mice administering a live adenovirus with encoded antigens and a specific immune stimulant to enhance the local immune response.

In the last few weeks, researchers at the University of Oxford in England have started a trial of a vaccine for the Coronavirus. It may be that, in the very near future, rather than the needle jab, we are using these micro patches instead for all vaccines.

Researchers from Harvard University in the USA are also working on a similar patch technology for the management of diabetes. The patch not only delivers insulin through the skin but also measures real-time blood sugar levels.

At present, the vast majority of insulin-dependent diabetics need to constantly prick their fingers to monitor blood sugar levels and then inject themselves on multiple occasions throughout the day. Again, over the next few years, the management of diabetes will be revolutionised by the use of these micro patches.

For many chronic conditions affecting millions of people, especially over the age of 50, the future of chronic medical management is very bright. When I started medical school in the 1970s, our medical and surgical therapies were modestly effective and I have seen a revolution in the management of chronic illnesses, such as cardiovascular disease and cancer, over the past 40 to 50 years.

With these extraordinary advances mentioned above, which are only a portion of what we will see over the next decade, the future of medicine is looking very bright indeed.

Read more from the original source:
The future of medicine - Switzer Financial News

The market research study titled Global Nanomedicine Market Size, Status and Forecast 2020-2026 brings you the most recent and the most updated data on the market. The report provides extensively researched information about the global Nanomedicine market structure, valuates, and outlines its variable aspects and applications. The report comprehensively represents the context of current and future trends driving the profit matrix. The report contains computable information, qualitative information sets, and evaluation tools. The research highlights major market insights, challenges, current trends, and value chain analysis.

The study provides estimates on global Nanomedicine market share, market size, and regional topography along with statistics, diagrams and charts explaining the differing interesting framework of the industry landscape. Divided by product type, applications, industry verticals, and research regions, the report research document delivers an explanation of the perspectives and comprehensive market statistics. It further covers the pricing of the product, production and consumption volume, cost analysis, industry value, barriers and growth drivers, major market players, demand and supply ratio of the market, the growth rate of the market and forecast from 2020 to 2026. Top players are completely profiled in this report.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/28942/request-sample

The major manufacturers covered in this report: Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences,

Regional Analysis For Market:

North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa) are leading countries and provide data like market share (%), sales (volume), imports & exports by types and applications, analysis, production, consumption, and consumption forecast. Information about different regions helps the reader to understand the global Nanomedicine market better.

Product type coverage (market size & forecast, a major company of product type etc.):

Application coverage (market size & forecast, different demand market by region, main consumer profile etc.): Segmentation encompasses oncology, Infectious diseases, Cardiology, Orthopedics, Other

Moreover, the report has included the leading merchants in this global Nanomedicine market everywhere throughout the world. In this part, market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue are determined. Additionally, upstream raw materials and downstream demand studies are administered. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The report further incorporates speculation attainability investigation and venture return investigation.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-nanomedicine-market-size-status-and-forecast-2020-2026-28942.html

Some of The Points Explained in The TOC of Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.magnifierresearch.com

See the original post here:
Global Nanomedicine Market by Type, Application, Element, & by Region Trends and Forecast to 2026 - Jewish Life News

Share

Share

Email

The research and development of antibiotics has been intense since their discovery in the early part of the past century.

However, in the last decade, there has been a dramatic shift in their effectiveness. More and more bacterial strains have developed resistance to antibiotics, and these resistant microorganisms are able to withstand the activity of commonly used antimicrobial drugs in a way that standard treatment becomes ineffective and infections persist. This increases the risk of their spread, which is clearly seen in clinical practice supported by World Health Organization annual reports.

The development of resistant strains is a natural phenomenon that occurs through selective pressure on the population of microorganisms. It is no surprise, then, that there is a general increase in the number of resistant microorganisms all around the world, although specific patterns vary considerably across countries.

Nanomaterials include a variable range of colloidal nanoparticles not only in terms of chemical composition but also in terms of shape and size, which significantly affect the desired properties their effect and biocompatibility, in particular. These properties can be customized during or after the preparation of nanoparticles according to the intended application.

Basic research includes the study of the relationship between morphology and physico-chemical and biological properties of nanomaterials, which form the theoretical basis for the design and synthesis of new generations of nanomaterials having specific applications in medicine. Due to their dimensions, nanoparticles are getting close to their target biological entities.

Current research in the field of nanomedicine focuses primarily on the rational transport of diagnostic and therapeutic agents to eliminate side effects and precisely target the desired location in the organism. Applications are not only available in human medicine but also in veterinary medicine and agriculture.

Dr. Smerkova and her colleagues from Mendel University in Brno, Czech Republic, have recently discussed current trends in the synthesis, development, and applications of advanced nanomaterials as alternatives to antibiotics. Although the active targeting of pathogens is a relatively emerging area, it has the potential to provide many benefits, including the improvement of therapeutic outcomes due to selectively targeting pathogens while sparing the human microbiome.

These aspects are inevitably associated with decreased side effects and reduction of socio-economical losses, and thus represent the golden grail of antibacterial treatment.

Besides these primary impacts, the fight against bacterial biofilm formation represents an important challenge for targeting strategies. The nanoparticles unique physicochemical properties allow them enhanced penetration through biofilm and to kill shielded bacteria by direct contact with intrinsic antibacterial nanomaterial or by antimicrobials delivery, explained Dr. Smerkova.

The targeting of intracellular pathogens surviving in hijacked macrophages is another special assignment of antimicrobial nanoparticles or nanocarriers loaded with antibiotics. On the other hand, due to their multicomponent and complex nature, actively targeted nanoparticles require a comprehensive understanding of their in-vivo stability, possible off-target effects, or loss of targeting ability due to protein corona formation and intracellular and organismal fate.

Dr. Smerkova also stated: For further acceleration of the development in the field of efficient targeting ligands for antibacterial nanoparticles, detailed knowledge of pathogen-specific surface structures needs to be gathered. In addition, high-throughput methods capable of screening for similarities with surface structures of common or uncommon members of the microbiome to achieve maximal selectivity are of an utmost interest.

Since science is experiencing the advent of superfast computational units capable of such screenings, it can be expected that virtual screening software will pave the way for novel targeting ligands based on a broad spectrum of various biomolecules. This would be a major leap forward and towards ligands that help generate an inexhaustible spectrum of novel antibacterial nanomaterials that could be used to combat the global threat posed by antibiotic-resistant bacteria.

Article written by Kristyna Smerkova, Kristyna Dolezelikova, Lucie Bozdechova, Zbynek Heger, Ludek Zurek, and Vojtech Adam

Reference: Kristyna Smerkova et al. Nanomaterials with active targeting as advanced antimicrobials. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1636

View post:
Does the dusk of old-school antibiotics mean the dawn of antimicrobial nanomaterials? - Advanced Science News

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the protocol for the first trial from its clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) has been designated as safe to proceed by the US Food and Drug Administration (FDA). The trial was co-developed with Nanobiotix and MD Anderson is the sponsor and executor of the trial.

The investigational new drug application (IND), covers a phase I study evaluating the safety and feasibility of NBTXR3 activated by radiation therapy for patients with locally advanced (LAPC) or borderline resectable (BRPC) cases of pancreatic ductal adenocarcinoma (PDAC). This trial is the first to evaluate NBTXR3 activated by radiation therapy in pancreatic cancer.

Significant Unmet Needs and Opportunity in Pancreatic Cancer

Pancreatic cancer is a rare, deadly disease. Given that surgery with R0 resection (i.e. macroscopically complete tumor removal with negative microscopic surgical margins) remains the only hope for long-term survival, clinical trials have investigated various neoadjuvant strategieswherein patients receive anti-cancer drugs or radiation prior to surgeryto increase the surgery-eligible population while also increasing the R0 resection rate.

In support of the rationale for neoadjuvant therapy, a retrospective analysis demonstrated a near doubling in overall survival (OS) in PDAC patients who underwent surgery, which was attributed, at least in part, to the increased proportion of BRPC patients who became eligible for surgery as a result of neoadjuvant intervention. Importantly, there are also select cases of LAPC patients being considered for surgical resection based on their response to therapy. Given the poor prognosis of PDAC, therapeutic regimens able to increase the proportion of BRPC and LAPC patients eligible for surgery could improve survival outcomes in this population with unmet need.

A Phase I Study Evaluating NBTXR3 Activated by Radiation Therapy in Patients with PADC

The MD Anderson trial is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the recommended phase 2 dose (RP2D); and (ii) expansion at RP2D.

The patient population will include adults (age 18 years) with BRPC or LAPC that are radiographically non-metastatic at screening, and that have not previously received radiation therapy or surgery for pancreatic cancer. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D. Up to 24 subjects will be enrolled, including a maximum of 12 subjects with LAPC for the dose-finding part. Twelve additional subjects with either LAPC or BRPC will be enrolled for the RP2D expansion. The planned enrollment period is 18 months. The first patient should be injected the summer of 2020.

The objectives of the study are the determination of dose-limiting toxicity (DLT), the maximum tolerated dose (MTD), and the RP2D.

About NBTXR3

NBTXR3 is a first-in-class product designed to destroy tumors through physical cell death when activated by radiotherapy. NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide radiation therapy standards of care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, pancreas, and breast cancers.

NBTXR3 is actively being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Promising results have been observed in the phase I trial regarding local control. In the United States, the company has started the regulatory IND process to commence a phase III clinical trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. Pursuant to an effective IND, the Company has launched a clinical trial of NBTXR3 activated by radiotherapy in combination with anti-PD-1 antibodies in locoregional recurrent (LRR) or recurrent and metastatic (R/M) HNSCC amenable to re-irradiation of the HN and lung or liver metastases (mets) from any primary cancer eligible for anti-PD-1.

The other ongoing NBTXR3 trials are treating patients with hepatocellular carcinoma (HCC) or liver metastases, locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma. The company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, lung, gastrointestinal and advanced cancers.

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

See the article here:
NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA - Business Wire

Researchers from IIT-Madras have developed a clove oil-based emulsion to treat cancer, claiming that the formulation would have enormous scope in the treatment of undifferentiated cancer and can also overcome anti-microbial resistance. The research papers were published recently in the reputed International Journal of Nanomedicine.The researchers, led by professor R Nagarajan, head, department of chemical engineering in IIT Madras, have developed a nano-scale emulsion of clove bud using the spontaneous self-emulsification technique with potent anti-cancer and antibacterial activity. This formulation meets all compliance requirements, they said. According to Nagarajan, while conventional therapies for cancer like radiation, chemotherapy and surgery cause severe damage to normal cells along with other major side-effects, the plant-based essential oils have paved way to devise innovative solutions to these drawbacks of synthetic drugs.The advantages of these emulsions lie in their small droplet size, ease of preparation, optical clarity, good physical stability, improved bio-availability, non-toxicity and non-irritability, said Nagarajan. This formulation would have an enormous scope in the treatment of metastatic cancer. Moreover, the components involved are cost-effective and demonstrate good efficacy, and the technique employed is simple, which is the utmost need for drug development, he said.The team of scientists includes M Joyce Nirmala, post doctoral fellow, Vineet Gopakumar, B Tech student, and Latha Durai, Research Scientistall from IIT-Madras.

See original here:
IIT-M develops oil-based cancer therapy - Times of India

By Nicole Bergot

A drug can prevent the virus responsible for the COVID-19 pandemic from replicating once inside an infected host, say researchers at the University of Alberta now searching for that magic bullet.

We aim to identify drugs that can be tested for effectiveness and safety in future trials, said Michael Woodside, a professor in the department of physics, using $370,700 in emergency funding from the Canadian Institutes of Health Research (CIHR) to find the elusive drug.

The plan is to screen first for drugs that are already approved for human use that could be repurposed to treat COVID-19 more quickly before broadening the search to potential drugs that are not currently approved.

Woodside explains that the genome of the novel coronavirus is made up of ribonucleic acid (RNA), not DNA so once inside an infected host, the virus inserts its RNA genome into the cell causing the creation of proteins the virus needs to replicate. And for all of this to occur, the novel coronavirus uses a process called programmed ribosomal frameshibing (PRF), a topic that Woodside, as a biophysicist, and his lab have been studying for years.

Researchers using laser tweezers to mimic what happens inside an infected cell were able to identify the mechanism through which PRF is triggered and now they can find molecular compounds to stop it from happening.

Most efforts to find drugs look for compounds that target the viral proteins directly, explains Woodside. Whats different about our approach is that we are targeting the virus through its RNA, rather than the proteins.

Woodside, inside the National Research Council of Canadas Nanotechnology Research Centre right here in Edmonton, is working closely with grad students, American counterparts, and Jack Tuszynski, a biophysics professor also in the department of physics, currently on secondment to the department of oncology in the faculty of medicine and dentistry.

Interdisciplinary research and scientific collaborations are essential to stopping the COVID-19 pandemic, said Woodside. Solutions have to engage expertise and approaches across a wide range of areas to understand the biophysics of the viral molecules, the biology of virus replication, the chemistry of drugs and their interactions with targets, the response of the immune system, the symptoms and epidemiology of the disease, and the response of patients to treatments.

Building and validating a model of the viral RNA for drug screening will occur over the next few months, with screening to identify approved drugs to follow before any potential candidates move toward preclinical tests.

Visit link:
'Laser tweezers' in nano lab used in search for drug to prevent COVID-19 replication - The Province